Area of research
Epidemiology · Hepatology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, Diet, Metabolism, and Disease, and Liver Diseases and Immunity.
Efficacy and safety of GLP-1 receptor agonists in MASH with fibrosis: A systematic review and meta-analysis
Association of Statin Use with Reduced Primary Liver Cancer Risk, Independent of Age and Cirrhosis Protection in MASLD.
Coagulation protease-activated receptor-2 (PAR2) promotes dyslipidemia, obesity and MASLD through repression of the hepatic pioneer factor HNF4α
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease
Current and emerging strategies for the prevention of hepatocellular carcinoma.
Age-specific protective effects of statins against cirrhosis in patients with chronic liver enzyme elevation associated with metabolic dysfunction: a retrospective cohort study of electronic health records
Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment
The Liver in Diabetes and Metabolic Syndrome.
Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis.
Peppermint oil-associated hepatotoxicity.
Betaine in the treatment of steatotic liver disease-Historical fad or a timeless treasure worth reviving?
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis.
The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
Alterations in zonal distribution and plasma membrane localization of hepatocyte bile acid transporters in patients with NAFLD
Alterations in zonal distribution and plasma membrane localization of hepatocyte bile acid transporters in patients with NAFLD
Steatotic liver disease, a useful construct in primary care that doesn't upset the apple cart.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study